Reply  by Chaitman, Bernard R.
LETTERS TO THE EDITOR
Pulmonary Hypertension After Toxic
Rapeseed Oil Ingestion
In connection with the article on pulmonary hypertension in
the toxic oil syndrome (I), we would like to comment on certain
points.
I) Toxicologic studies (2) indicate that there is no evidence
that inhalation is a possible means of entry; the digestive route is
the only one accepted.
2) The authors mention a leukocytoclastic vasculitis of the
small vessels with secondary thromboses. Leukocytoclasia and
fibrinoid necrosis have never been described in the vascular lesion
of the toxic oil syndrome (3), which affects vessels of all sizes.
3) Pulmonary hypertension was first observed in June 1981, I
month after the clinical picture first appeared (May 1981). The
frequency of pulmonary hypertension at that time in a sample of
1,300 patients was 9.4% with the diagnosis based on clinical
findings and noninvasive methods, and increased to 20% in hos-
pitalized patients. After 6 months, the frequency began to decrease,
and after 18 months another study (4) carried out with invasive
methods on 200 patients selected at random yielded a frequency
of 3.5%.
In the majority of patients, the course tended toward improve-
ment, and there was no demonstrated connection with different
therapies. This favorable spontaneous development, which has
continued to the present time, has been an argument against ag-
gressive therapeutic action.
The pulmonary lesion manifests edema, interstitial infiltrates,
alveolar edema, limphangiectasia and vascular involvement similar
to that 0: the rest of the organism. To date, pulmonary fibrosis
has not been observed even in autopsies performed on patients
with pulmonary hypertension.
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Reply
We described the occurrence of pulmonary hypertension in a
subset of patients after toxic rapeseed oil ingestion which, in some
patients, persisted as long as 6 months. The Spanish subcommis-
sion on epidemiologic studies has confirmed that this entity occurs
in approximately 9% of patients and in as much as 20% of patients
who are hospitalized for this syndrome. At the time we wrote our
report, some of the information that the committee has brought
forth was unavailable. It would appear from their comments that
toxicity studies have shown that the main route of toxicity is
ingestion, and that the agent is most likely oleoanilide and not
erucic acid to which we alluded in our report,
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